A durable limb salvage and functional recovery after prolonged prostaglandin E1 therapy following femoro-popliteal bypass graft thrombosis: a one-year follow-up case report

Authors

  • Shoaeb Imtiaz Alam Department of Vascular Surgery, Dhaka Medical College and Hospital, Dhaka, Bangladesh
  • Istiaq Ahmed Department of Cardiac Surgery, Dhaka Medical College and Hospital, Dhaka, Bangladesh
  • Manjurul Hasan Department of Vascular Surgery, Dhaka Medical College Hospital, Dhaka, Bangladesh
  • Mufrid Kashem Department of Vascular Surgery, Dhaka Medical College and Hospital, Dhaka, Bangladesh
  • M. Zahin Arefin Department of Vascular Surgery, Dhaka Medical College and Hospital, Dhaka, Bangladesh
  • Sonia Anjum Department of Vascular Surgery, Dhaka Medical College and Hospital, Dhaka, Bangladesh
  • Kazi Al-Hosne Jamil Department of Cardiac Surgery, Dhaka Medical College and Hospital, Dhaka, Bangladesh

DOI:

https://doi.org/10.18203/2349-2902.isj20263862

Keywords:

Prostaglandin E1, Femoropopliteal bypass, Graft thrombosis, Chronic limb-threatening ischemia, Collateral circulation, Limb salvage

Abstract

Infrainguinal bypass graft thrombosis can cause recurrent limb ischemia, tissue loss, and major amputation. A 65-year-old man with diabetes, hypertension, and previous cigarette smoking developed complete thrombosis of a Dacron femoropopliteal bypass graft six months after surgery. Pharmacogenetic testing identified a CYP2C19 intermediate-metabolizer phenotype associated with reduced clopidogrel responsiveness. Clopidogrel was discontinued, while aspirin and rivaroxaban were continued, and intravenous prostaglandin E1 (PGE1; alprostadil) therapy was initiated. Following three previously reported cycles, he completed six total cycles, each administered over three consecutive days at approximately four-week intervals. At one-year follow-up after treatment completion, he remained free of ischemic pain, ulceration, gangrene, and tissue loss, avoiding major amputation and repeat revascularization. He could walk more than 200 m and had Rutherford category 0 status. Follow-up computed tomography angiography demonstrated collateral vessels from the deep femoral circulation. This case highlights sustained limb preservation following prolonged PGE1 therapy despite graft thrombosis.

Metrics

Metrics Loading ...

References

Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69(6 Suppl):3S-125S.e40. DOI: https://doi.org/10.4103/ijves.ijves_50_19

Gornik HL, Aronow HD, Goodney PP, Arya S, Brewster LP, Byrd L, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease. Circulation. 2024;149:e1313-410. DOI: https://doi.org/10.1161/CIR.0000000000001251

Haga M, Shindo S, Motohashi S, et al. Early evaluation of the infrainguinal revascularization strategy selection tool of the Global Vascular Guidelines for chronic limb-threatening ischemia patients. J Vasc Surg. 2021;74(4):1253-60.e2. DOI: https://doi.org/10.1016/j.jvs.2021.04.034

Almasri J, Adusumalli J, Asi N, et al. A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia. J Vasc Surg. 2018;68(2):624-33. DOI: https://doi.org/10.1016/j.jvs.2018.01.066

Ruffolo AJ, Romano M, Ciapponi A. Prostanoids for critical limb ischaemia. Cochrane Database Syst Rev. 2010;(1):CD006544. DOI: https://doi.org/10.1002/14651858.CD006544.pub2

Vietto V, Franco JVA, Saenz V, Cytryn D, Chas J, Ciapponi A. Prostanoids for critical limb ischaemia. Cochrane Database Syst Rev. 2018;1:CD006544. DOI: https://doi.org/10.1002/14651858.CD006544.pub3

Creutzig A, Lehmacher W, Elze M. Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV. Vasa. 2004;33(3):137-44. DOI: https://doi.org/10.1024/0301-1526.33.3.137

Bedenis R, Lethaby A, Maxwell H, Acosta S, Prins MH. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev. 2015;2015(2):CD000535.

Belch JJF, Dormandy J, CASPAR Writing Committee, Biasi G, Cairols M, Diehm C, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010;52(4):825-33.e2. DOI: https://doi.org/10.1016/j.jvs.2010.04.027

Ahmed I, Reza MM, Rahman T, Rahman CMM, Jamil KA-H, Hasan M, et al. Graft thrombosis after revascularization due to CYP2C19 polymorphism and clopidogrel resistance: a rare case report. Asian J Case Rep Surg. 2025;8(1):294-300. DOI: https://doi.org/10.9734/ajcrs/2025/v8i1639

Altstaedt HO, Berzewski B, Taschke C. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukot Essent Fatty Acids. 1993;49(2):573-8. DOI: https://doi.org/10.1016/0952-3278(93)90163-Q

Meini S, Dentali F, Melillo E, de Donato G, Mumoli N, Mazzone A, et al. Prostanoids for critical limb ischemia: a clinical review and consideration of current guideline recommendations. Angiology. 2020;71(3):202-11. DOI: https://doi.org/10.1177/0003319719889273

Lawall H, Pokrovsky A, Checinski P, Ratushnyuk A, Hamm G, Randerath O, et al. Efficacy and safety of alprostadil in patients with peripheral arterial occlusive disease Fontaine stage IV: results of a placebo controlled randomised multicentre trial (ESPECIAL). Eur J Vasc Endovasc Surg. 2017;53(4):559-66. DOI: https://doi.org/10.1016/j.ejvs.2016.12.035

Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382(21):1994-2004. DOI: https://doi.org/10.1056/NEJMoa2000052

Debus ES, Nehler MR, Govsyeyev N, Bauersachs R, Anand SS, Patel MR, et al. Effect of rivaroxaban and aspirin in patients with peripheral artery disease undergoing surgical revascularization: insights from the VOYAGER PAD trial. Circulation. 2021;144(14):1104-16. DOI: https://doi.org/10.1161/CIRCULATIONAHA.121.054835

Downloads

Published

2026-10-27

How to Cite

Alam, S. I., Ahmed, I., Hasan, M., Kashem, M., Arefin, M. Z., Anjum, S., & Jamil, K. A.-H. (2026). A durable limb salvage and functional recovery after prolonged prostaglandin E1 therapy following femoro-popliteal bypass graft thrombosis: a one-year follow-up case report. International Surgery Journal, 13(11), 2253–2257. https://doi.org/10.18203/2349-2902.isj20263862

Issue

Section

Case Reports